Page 99 - Read Online

Porcari et al. Vessel Plus 2022;6:33 https://dx.doi.org/10.20517/2574-1209.2021.134 Page 11 of 14

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International
Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2020;27:217-22. DOI PubMed
2. Porcari A, Merlo M, Rapezzi C, Sinagra G. Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery. Eur J
Intern Med 2020;82:7-15. DOI PubMed PMC
3. Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac
amyloidosis. Circ Heart Fail 2019;12:e006075. DOI PubMed PMC
4. Emdin M, Aimo A, Rapezzi C, et al. Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J 2019;40:3699-706. DOI
PubMed
5. Merlo M, Porcari A, Pagura L, et al. A national survey on prevalence of possible echocardiographic red flags of amyloid
cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization-the first
insight from the AC-TIVE Study. Eur J Prev Cardiol 2021;zwab127. DOI PubMed
6. Kastritis E, Palladini G, Minnema MC, et al; ANDROMEDA Trial Investigators. Daratumumab-based treatment for immunoglobulin
light-chain amyloidosis. N Engl J Med 2021;385:46-58. DOI PubMed
7. Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with
symptomatic heart failure. J Am Coll Cardiol 2016;67:2941-8. DOI PubMed
8. Maurer MS, Schwartz JH, Gundapaneni B, et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin
amyloid cardiomyopathy. N Engl J Med 2018;379:1007-16. DOI PubMed
9. Korosoglou G, Giusca S, André F, et al. Diagnostic work-up of cardiac amyloidosis using cardiovascular imaging: current standards
and practical algorithms. Vasc Health Risk Manag 2021;17:661-73. DOI PubMed PMC
10. Porcari A, Falco L, Lio V, et al. Cardiac amyloidosis: do not forget to look for it. Eur Heart J Suppl 2020;22:E142-7. DOI PubMed
PMC
11. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with
preserved ejection fraction. Eur Heart J 2015;36:2585-94. DOI PubMed
12. Porcari A, Pagura L, Longo F, et al. Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal
tunnel surgery. ESC Heart Fail 2021. DOI PubMed
13. Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with
severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879-87. DOI PubMed PMC
14. Nietlispach F, Webb JG, Ye J, et al. Pathology of transcatheter valve therapy. JACC Cardiovasc Interv 2012;5:582-90. DOI PubMed
15. Visser RAB, Gravenor C, Ahmed S, Harky A. Amyloidosis and cardiovascular diseases: a clinical insight. J Card Surg 2021;36:522-9.
DOI PubMed
16. Porcari A, Bussani R, Merlo M, et al. Incidence and characterization of concealed cardiac amyloidosis among unselected elderly
patients undergoing post-mortem examination. Front Cardiovasc Med 2021;8:1680. DOI PubMed PMC
17. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an
increase in cellular oxidant stress. Circ Res 2004;94:1008-10. DOI PubMed
18. Koike H, Katsuno M. The ultrastructure of tissue damage by amyloid fibrils. Molecules 2021;26:4611. DOI PubMed PMC
19. Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies.
Neurol Ther 2020;9:317-33. DOI PubMed PMC
20. Mendes Sousa M, Cardoso I, Fernandes R, Guimarães A, Saraiva MJ. Deposition of transthyretin in early stages of familial
amyloidotic polyneuropathy. Am J Pathol 2001;159:1993-2000. DOI
21. Kittleson MM, Maurer MS, Ambardekar AV, et al; American Heart Association Heart Failure and Transplantation Committee of the